All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cemiplimab Plus Chemotherapy Yields Responses in Advanced/Metastatic Penile Carcinoma

March 11th 2025

Cemiplimab-based therapy is effective and has a safety profile consistent with prior reports in locally advanced/metastatic penile cancer.

Acalabrutinib Plus Bendamustine and Rituximab Displays Long-Term Activity in Frontline and R/R MCL

March 11th 2025

Acalabrutinib plus BR showed OS and PFS efficacy with a tolerable safety profile with long-term follow-up in first-line and R/R MCL.

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer

March 10th 2025

ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer

March 10th 2025

T-DXd with or without pertuzumab produced responses in first-line, HER2-positive metastatic breast cancer.

Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC

March 10th 2025

Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.

Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups

March 10th 2025

Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC

March 10th 2025

The Chinese NMPA has approved sacituzumab tirumotecan for EGFR-mutant advanced NSCLC following progression on an EGFR TKI and chemotherapy.

China’s NMPA Accepts MAA for Foritinib in ALK+ Advanced NSCLC

March 10th 2025

China’s NMPA has accepted an MAA seeking the approval of foritinib for ALK-positive advanced non–small cell lung cancer.

Latent Viruses in Human Genome Inspire Novel Directions for Kidney Cancer Immunotherapy

March 10th 2025

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in ccRCC.

Novel Index Identifies Social Vulnerability Barriers to Cancer Clinical Trial Enrollment

March 10th 2025

Lower odds of enrollment in cancer clinical trials could be associated with education, transportation, and neighborhood resources.

Zongertinib Displays Early Activity and Tolerability in HER2-Mutated Solid Tumors

March 10th 2025

Zongertinib showed responses across HER2-mutated tumor types, including in lung cancer, with a tolerable safety profile.

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer

March 9th 2025

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer

March 9th 2025

Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

Five Under 5: Top Oncology Videos for the Week of 3/2

March 9th 2025

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

The OncFive: Top Oncology Articles for the Week of 3/2

March 9th 2025

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.

Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases

March 8th 2025

Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions

March 8th 2025

Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Same-Day Dosing of Eflapegrastim and Chemotherapy Is Safe, Reduces Duration of Severe Neutropenia in Early-Stage Breast Cancer

March 8th 2025

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

International Women’s Day Highlights Importance of Female Mentorship for Early-Career Women in Oncology

March 8th 2025

Megan Melody, MD, discusses her journey as an oncologist and the importance of mentorship and a supportive work environment to empower women in the field.

Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups

March 8th 2025

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.